loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations
IPOLogoImag

GOLDLINE PHARMACEUTICAL IPO

CLOSED

IPO Details

12th May 2026
14th May 2026
3,000
₹ 2,58,000
₹ 41-43
₹ 12 Crore

Issue timeline

  • 12-14 May 2026
  • 15-May-2026
  • 18-May-2026
  • 18-May-2026
  • 19-May-2026

Subscription Status

Shareholder -
Qualified Institutional Buyers -
Non-Institutional Investor -
Retail Individual Investor -
Employee -
Total -

About Company

Goldline Pharmaceutical Limited is a specialized pharmaceutical marketing company headquartered in Mumbai. The company operates through an asset-light business model, partnering with 15 third-party manufacturers to produce a diversified portfolio of medications under the proprietary “Goldline” brand. Its operations are spearheaded by promoters with over 25 years of industry experience, focusing on market research, demand analysis, and distribution. The company’s product portfolio is organized into five strategic divisions:

  • Goldline Pharma: Multi-specialty products for routine prescribing patterns.
  • Goldline Cardinal: Therapies for chronic lifestyle diseases like diabetes and cardiovascular disorders.
  • Goldline Aayushman: Specialized offerings for gynecology and pediatrics.
  • Goldline InLife: Critical care and injectable products for hospital and ICU settings.
  • Goldline Wellness: Supportive care and adjunct therapies for oncology patients.

With a distribution network of 8 key distributors, Goldline maintains a significant market presence across Maharashtra, Madhya Pradesh, Odisha, and four other Indian states, providing comprehensive supply chain support to healthcare partners.

2004
Amol Laxmikant Mujumdar

Objectives

Prepayment or repayment of all or a portion of certain outstanding borrowings availed by the company
General corporate purposes

Strengths & Risks

Strengths (4)

Experienced Leadership: Guided by a management team with over five decades of combined experience in pharmaceutical marketing and distribution, providing deep technical and operational expertise.

Risks (4)

Contract Manufacturing Reliance: The company outsources all production to third-party manufacturers. Any failure by these partners to meet quality, regulatory, or capacity standards could directly disrupt operations and financial performance.

Financials

Industry Overview

  • Global Leadership in Volume: The Indian pharmaceutical industry ranks 3rd globally in production volume and 14th in value, contributing approximately 1.72% to the national GDP and accounting for 20% of global generic drug exports.
  • Exponential Growth Projections: Currently valued at ~US$ 50 billion, the market is projected to reach US$ 130 billion by 2030 and US$ 450 billion by 2047, driven by an 8% growth in exports to over 200 nations.
  • Government-Led Infrastructure: Growth is accelerated by significant budgetary increases in Bulk Drug and Medical Device Parks, alongside the expansion of the Jan Aushadhi scheme to enhance the affordability and reach of generic medications.

Goldline Pharmaceutical IPO FAQs

What is the Goldline Pharmaceutical IPO opening date?

The Goldline Pharmaceutical IPO is scheduled to open for public subscription on May 12, 2026, and close on May 14, 2026.

The price band for Goldline Pharmaceutical IPO has been fixed in the range of ₹41 to ₹43 per equity share.

The minimum lot size for Goldline Pharmaceutical IPO is 3000, and the minimum amount required for application is ₹2,58,000, with 2 lots being the minimum application size.

The promoters of the company are Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal.

The shares are proposed to be listed on the BSE and SME.

View More

*The financials mentioned above are sourced from DRHP/ RHP documents.